MYLK and colon adenocarcinoma: SRRM2 is upregulated in colon adenocarcinoma, predicting poor prognosis [20], and its silencing inhibits angiogenesis in nasopharyngeal carcinoma through MYLK-mediated cGMP-PKG signaling pathway [21].